繁體版 / 簡體版
 
R&D PORTFOLIO
/ SNP-830、SNP-840

SNP-830、SNP-840

Indication
Hepatotoxicity-free Analgesic
Product Advantages
1. Hepatotoxicity-free Acetaminophen prescription Combo
2. A new combination with great safety margin
Status
After the approval of SNP-810 Plan a clinical trial with / without bioequivalent study for NDA
Competitive Edge
1. No hepatotoxicity-free acetaminophen prescription Combo on the market
2. Acetaminophen prescription combos were requested by USFDA to reduce the dose to below 325 mg ( potency affected )
3. Remove or modify the FDA liver warning
4. Regain the AAP dose to 500 mg or more
5. Grab the market of other pain controllers
6. The two choose one license
Potential Market
Acetaminophen prescription Combo sales are 2.7 billion USD a year (US only)


陕西快乐十分中奖技巧 甘肃快三遗漏查询 6场半全场胜负12137期 004期特码资料 (*^▽^*)MG热力宝石APP下载 河内五分彩是不是自己平台开奖 快开彩票停售实体店怎么办 (★^O^★)MG丛林巨兽游戏 新疆35选7重号走势图 (★^O^★)MG黄金工厂_电子游艺 (★^O^★)MG银弹游戏 黄大仙灵签三肖中特期期中王 (*^▽^*)MG昆虫派对游戏说明 131期湖北福彩30选5 今天上海快3开奖结果 (^ω^)MG北极特务首页 (*^▽^*)MG黄金翅膀技巧介绍